Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapyDouglas B. Johnson, Justin M. Balko, Violeta Sánchez et al.|Nature Communications|2016Cited by 572
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trialAssuntina G. Sacco, Ezra E.W. Cohen, Ruifeng Chen et al.|The Lancet Oncology|2021Cited by 257